ketamine has been researched along with Alcohol Abuse in 38 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Worldwide, alcohol abuse is a burgeoning problem." | 2.84 | A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial. ( Brandner, B; Lawn, W; McAndrew, A; Morgan, CJ; Porffy, L; Stevens, T, 2017) |
| "Alcohol use disorder is highly prevalent and has important economical, societal, psychiatric, and medical consequences." | 2.82 | Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions. ( Garel, N; Greenway, KT; Jutras-Aswad, D; Lesperance, P; McAnulty, C; Miron, JP; Rej, S; Richard-Devantoy, S, 2022) |
| "Subjects with a family history of alcohol dependence showed significantly greater improvement in MADRS scores compared with subjects who had no family history of alcohol dependence." | 2.74 | Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. ( Brutsche, N; Luckenbaugh, DA; Manji, HK; Moral, JR; Phelps, LE; Zarate, CA, 2009) |
| "Ketamine is a N-methyl-D-Aspartate receptor antagonist, historically used in anesthesia, but also affects other neurotransmitters systems, synaptic plasticity, neurogenesis, and neural connectivity." | 2.72 | Therapeutic potential of ketamine for alcohol use disorder. ( Gould, TJ; Worrell, SD, 2021) |
| "Nimodipine pretreatment attenuated the perceived similarity of ketamine effects to ethanol as well as ketamine-induced euphoria and sedation." | 2.70 | Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. ( Burakov, AM; Fletcher, J; Grinenko, AY; Grinenko, NI; Krupitsky, EM; Krystal, JH; Petrakis, IL; Romanova, TN, 2001) |
| "Ketamine effects also were more like ethanol than marijuana or cocaine." | 2.69 | Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. ( Charney, DS; Cooney, NL; Karper, LP; Krystal, JH; Namanworth, S; Petrakis, IL; Stetson, P; Trevisan, LA; Webb, E, 1998) |
| "Problematic compounds may cause seizures either acutely or on withdrawal: Their use may reduce effectiveness of antiepileptic drugs, or may simply promote and enhance chaotic lifestyles." | 2.48 | Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention. ( Borland, W; Leach, JP; Mohanraj, R, 2012) |
| "Alcohol use disorder is prevalent globally and in Kenya, and is associated with significant health and socio-economic consequences." | 1.91 | Intravenous ketamine for severe alcohol use disorder at Moi Teaching & Referral Hospital, Kenya: a case report. ( Andale, T; Aruasa, WK; Gakinya, B; Jaguga, F; Kerema, J; Kinyanjui, D; Kirwa, P; Kwobah, C; Kwobah, EK; Manji, I; Mwangi, F; Songok, J; Temet, E; Werunga, K, 2023) |
| "During drinking of 40% alcohol, the AUC(0-t), AUC(0-∞), and Cmax of ketamine and norketamine significantly increased, while V and CL significantly decreased with time (p < 0." | 1.62 | Effects of long-term alcohol exposure on the pharmacokinetic profiles of ketamine and norketamine in rats. ( Chen, Y; Hu, L; Wen, C; Wu, Y; Ying, L; Zhong, Z, 2021) |
| "(R)-ketamine alone was tested at the highest dose studied (10 mg/kg) and did not significantly influence any dependent measure." | 1.62 | Rapid tolerance to behavioral effects of ethanol in rats: Prevention by R-(-)-ketamine. ( Holuj, M; Kaniecki, K; Krawczyk, M; Kuziak, A; Popik, P; Shafique, H; Smith, JL; Sporn, J; Witkin, JM, 2021) |
| "A key feature of alcohol use disorder (AUD) is negative affect during withdrawal, which often contributes to relapse and is thought to be caused by altered brain function, especially in circuits that are important mediators of emotional behaviors." | 1.56 | Withdrawal from chronic ethanol exposure increases postsynaptic glutamate function of insular cortex projections to the rat basolateral amygdala. ( McCool, BA; McGinnis, MM; Parrish, BC, 2020) |
| "Ketamine has rapid antidepressant properties in major depressive disorder (MDD) as well as bipolar depression." | 1.38 | Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. ( Brutsche, N; Cassarly, C; Franco-Chaves, J; Ibrahim, L; Luckenbaugh, DA; Marquardt, CA; Mathews, D; Zarate, CA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.63) | 18.7374 |
| 1990's | 3 (7.89) | 18.2507 |
| 2000's | 9 (23.68) | 29.6817 |
| 2010's | 12 (31.58) | 24.3611 |
| 2020's | 13 (34.21) | 2.80 |
| Authors | Studies |
|---|---|
| Grabski, M | 1 |
| McAndrew, A | 2 |
| Lawn, W | 2 |
| Marsh, B | 1 |
| Raymen, L | 1 |
| Stevens, T | 2 |
| Hardy, L | 1 |
| Warren, F | 1 |
| Bloomfield, M | 1 |
| Borissova, A | 1 |
| Maschauer, E | 1 |
| Broomby, R | 1 |
| Price, R | 1 |
| Coathup, R | 1 |
| Gilhooly, D | 1 |
| Palmer, E | 1 |
| Gordon-Williams, R | 1 |
| Hill, R | 1 |
| Harris, J | 1 |
| Mollaahmetoglu, OM | 1 |
| Curran, HV | 1 |
| Brandner, B | 2 |
| Lingford-Hughes, A | 1 |
| Morgan, CJA | 1 |
| Garel, N | 1 |
| McAnulty, C | 1 |
| Greenway, KT | 1 |
| Lesperance, P | 1 |
| Miron, JP | 1 |
| Rej, S | 1 |
| Richard-Devantoy, S | 1 |
| Jutras-Aswad, D | 1 |
| Terasaki, D | 3 |
| Loh, R | 3 |
| Cornell, A | 3 |
| Taub, J | 3 |
| Thurstone, C | 3 |
| Jaguga, F | 1 |
| Kirwa, P | 1 |
| Gakinya, B | 1 |
| Manji, I | 1 |
| Andale, T | 1 |
| Kinyanjui, D | 1 |
| Kwobah, EK | 1 |
| Mwangi, F | 1 |
| Werunga, K | 1 |
| Kerema, J | 1 |
| Kwobah, C | 1 |
| Temet, E | 1 |
| Songok, J | 1 |
| Aruasa, WK | 1 |
| da Silveira, CCM | 1 |
| Cartágenes, SC | 1 |
| Kobayashi, NHC | 1 |
| Farias, SV | 1 |
| de Souza-Junior, FJC | 1 |
| Fernandes, LMP | 1 |
| do Prado, AF | 1 |
| Aragão, WAB | 1 |
| Lima, RR | 1 |
| Ferreira, WAS | 1 |
| de Oliveira, EHC | 1 |
| Mello Júnior, FAR | 1 |
| Burbano, RMR | 1 |
| Fontes-Júnior, EA | 1 |
| Maia, CDSF | 1 |
| Hilal, F | 1 |
| Jeanblanc, J | 1 |
| Naassila, M | 1 |
| Egerton, A | 1 |
| Dakwar, E | 1 |
| Levin, F | 1 |
| Hart, CL | 1 |
| Basaraba, C | 1 |
| Choi, J | 1 |
| Pavlicova, M | 1 |
| Nunes, EV | 1 |
| Mathew, SJ | 1 |
| Price, RB | 1 |
| McGinnis, MM | 1 |
| Parrish, BC | 1 |
| McCool, BA | 1 |
| Ying, L | 1 |
| Chen, Y | 1 |
| Zhong, Z | 1 |
| Wu, Y | 1 |
| Hu, L | 1 |
| Wen, C | 1 |
| Shafique, H | 1 |
| Witkin, JM | 1 |
| Smith, JL | 1 |
| Kaniecki, K | 1 |
| Sporn, J | 1 |
| Holuj, M | 1 |
| Krawczyk, M | 1 |
| Kuziak, A | 1 |
| Popik, P | 1 |
| Worrell, SD | 1 |
| Gould, TJ | 1 |
| Porffy, L | 1 |
| Morgan, CJ | 1 |
| Yoon, G | 3 |
| Petrakis, IL | 8 |
| Krystal, JH | 9 |
| Heifets, BD | 2 |
| Williams, NR | 2 |
| Blasey, C | 1 |
| Sudheimer, K | 1 |
| Rodriguez, CI | 1 |
| Schatzberg, AF | 2 |
| Bentzley, BS | 1 |
| Pittman, B | 1 |
| Limoncelli, D | 3 |
| Aksay, SS | 1 |
| Hambsch, M | 1 |
| Janke, C | 1 |
| Bumb, JM | 1 |
| Kranaster, L | 1 |
| Sartorius, A | 1 |
| Phelps, LE | 1 |
| Brutsche, N | 2 |
| Moral, JR | 1 |
| Luckenbaugh, DA | 2 |
| Manji, HK | 1 |
| Zarate, CA | 2 |
| Sanders, B | 1 |
| Lankenau, SE | 1 |
| Jackson-Bloom, J | 1 |
| Hathazi, D | 1 |
| Wilkins, LK | 1 |
| Girard, TA | 1 |
| Cheyne, JA | 1 |
| van Amsterdam, JG | 1 |
| Brunt, TM | 1 |
| McMaster, MT | 1 |
| Niesink, RJ | 1 |
| Leach, JP | 1 |
| Mohanraj, R | 1 |
| Borland, W | 1 |
| Ibrahim, L | 1 |
| Franco-Chaves, J | 1 |
| Mathews, D | 1 |
| Marquardt, CA | 1 |
| Cassarly, C | 1 |
| Chow, C | 1 |
| Vallance, K | 1 |
| Stockwell, T | 1 |
| Macdonald, S | 1 |
| Martin, G | 1 |
| Ivsins, A | 1 |
| Marsh, DC | 1 |
| Michelow, W | 1 |
| Roth, E | 1 |
| Duff, C | 1 |
| Webb, E | 2 |
| Gueorgueva, R | 1 |
| D'Souza, DC | 3 |
| Boutros, NN | 2 |
| Trevisan, L | 3 |
| Charney, DS | 2 |
| Krupitsky, E | 1 |
| Schutz, C | 1 |
| Gueorguieva, R | 2 |
| Jatlow, P | 1 |
| Gelernter, J | 1 |
| Madonick, S | 1 |
| Perry, E | 1 |
| Brush, L | 1 |
| Wray, Y | 1 |
| Belger, A | 1 |
| Pavarin, RM | 1 |
| Sivolap, IuP | 1 |
| Savchenkov, VA | 1 |
| Krupitskiĭ, EM | 2 |
| Grinenko, AIa | 2 |
| Cooney, NL | 1 |
| Karper, LP | 1 |
| Namanworth, S | 1 |
| Stetson, P | 1 |
| Trevisan, LA | 1 |
| Schütz, CG | 1 |
| Soyka, M | 1 |
| Krupitsky, EM | 1 |
| Burakov, AM | 1 |
| Romanova, TN | 1 |
| Grinenko, NI | 1 |
| Grinenko, AY | 1 |
| Fletcher, J | 1 |
| Paleĭ, AI | 1 |
| Petrov, VN | 1 |
| Moshkov, KA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomised, Double-blind, Placebo- Controlled, Multi-site, Parallel Group Clinical Trial to Examine Ketamine as a Pharmacological Treatment for Alcohol Dependence in an Alcohol Dependent Population[NCT02649231] | Phase 2 | 96 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| The Effect of Brief Potent Glutamatergic Modulation on Disordered Alcohol Use[NCT02539511] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| NMDA Dysregulation in Individuals With a Family Vulnerability to Alcoholism[NCT00588952] | 99 participants (Actual) | Interventional | 2001-03-31 | Completed | |||
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| Study of the Efficacity of the Systemic Ketamine for the Improvement of Post-Operative Analgesia After ORL Carcinological Surgery at the Alcohol-Dependent Patient.[NCT00329394] | Phase 3 | 56 participants (Anticipated) | Interventional | 2006-04-30 | Suspended | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time line follow back (NCT02649231)
Timeframe: 6 months
| Intervention | percentage of days abstinent (Mean) |
|---|---|
| Ketamine+Psychological Therapy | 86.4 |
| Ketamine+Education | 82.5 |
| Placebo+Psychological Therapy | 78.3 |
| Placebo+Education | 70.7 |
Time line follow back (NCT02649231)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine+Psychological Therapy | 13 |
| Ketamine+Education | 15 |
| Placebo+Psychological Therapy | 14 |
| Placebo+Education | 18 |
Percentage of participants demonstrating alcohol abstinence in the control (midazolam) group versus the active (ketamine) group (NCT02539511)
Timeframe: 21 days post-infusion
| Intervention | percentage of participants (Number) |
|---|---|
| Control Group: Midazolam+MET | 68.6 |
| Active Group: Ketamine+MET | 98.6 |
Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 15 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 24.74 | 1.36 |
| Family History Positive | 18.96 | 2.46 |
Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 45 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 25.06 | 1.64 |
| Family History Positive | 18.36 | 1.46 |
Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 80 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 9.99 | 0.92 |
| Family History Positive | 7.46 | 1.07 |
Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 0.96 | 1.25 |
| Family History Positive | 0.63 | 0.71 |
Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 15 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 14.58 | 1.82 |
| Family History Positive | 22.39 | 1.82 |
Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 45 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 9.06 | 1.64 |
| Family History Positive | 15.4 | 1.54 |
Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: 80 minutes
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 3.02 | 2.12 |
| Family History Positive | 3.81 | 1.61 |
Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. (NCT00588952)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ketamine | Placebo | |
| Family History Negative | 2.43 | 2.88 |
| Family History Positive | 3.78 | 2.36 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
7 reviews available for ketamine and Alcohol Abuse
| Article | Year |
|---|---|
Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions.
Topics: Adult; Alcohol Drinking; Alcoholism; Craving; Humans; Ketamine; Substance Withdrawal Syndrome | 2022 |
[Interest and mechanisms of action of ketamine in alcohol addiction- A review of clinical and preclinical studies].
Topics: Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Ethanol; Female; Hallucinogens; Human | 2023 |
The potential of
Topics: Acamprosate; Alcoholism; Brain; Central Nervous System Agents; Drug Development; Glutamic Acid; Huma | 2021 |
Therapeutic potential of ketamine for alcohol use disorder.
Topics: Adult; Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Receptors, N | 2021 |
Possible long-term effects of γ-hydroxybutyric acid (GHB) due to neurotoxicity and overdose.
Topics: Alcoholism; Anesthetics; Anesthetics, Dissociative; Animals; Central Nervous System Depressants; Cog | 2012 |
Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention.
Topics: Alcohol Drinking; Alcohol Withdrawal Seizures; Alcoholism; Amphetamine-Related Disorders; Benzodiaze | 2012 |
NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy.
Topics: Alcoholic Intoxication; Alcoholism; Animals; Ethanol; Excitatory Amino Acid Antagonists; Humans; Ket | 2003 |
13 trials available for ketamine and Alcohol Abuse
| Article | Year |
|---|---|
Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Ketamine; Male; Recurrence | 2022 |
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.
Topics: Adolescent; Adult; Aged; Alcoholism; Feasibility Studies; Humans; Inpatients; Ketamine; Middle Aged; | 2022 |
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.
Topics: Adolescent; Adult; Aged; Alcoholism; Feasibility Studies; Humans; Inpatients; Ketamine; Middle Aged; | 2022 |
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.
Topics: Adolescent; Adult; Aged; Alcoholism; Feasibility Studies; Humans; Inpatients; Ketamine; Middle Aged; | 2022 |
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.
Topics: Adolescent; Adult; Aged; Alcoholism; Feasibility Studies; Humans; Inpatients; Ketamine; Middle Aged; | 2022 |
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.
Topics: Adolescent; Adult; Aged; Alcoholism; Feasibility Studies; Humans; Inpatients; Ketamine; Middle Aged; | 2022 |
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.
Topics: Adolescent; Adult; Aged; Alcoholism; Feasibility Studies; Humans; Inpatients; Ketamine; Middle Aged; | 2022 |
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.
Topics: Adolescent; Adult; Aged; Alcoholism; Feasibility Studies; Humans; Inpatients; Ketamine; Middle Aged; | 2022 |
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.
Topics: Adolescent; Adult; Aged; Alcoholism; Feasibility Studies; Humans; Inpatients; Ketamine; Middle Aged; | 2022 |
Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.
Topics: Adolescent; Adult; Aged; Alcoholism; Feasibility Studies; Humans; Inpatients; Ketamine; Middle Aged; | 2022 |
A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial.
Topics: Alcoholism; Combined Modality Therapy; Double-Blind Method; Female; Humans; Infusions, Intravenous; | 2020 |
A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial.
Topics: Adolescent; Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Doub | 2017 |
Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder.
Topics: Adult; Alcohol Drinking; Alcoholism; Craving; Depressive Disorder, Major; Drug Therapy, Combination; | 2019 |
Familial Alcoholism Risk and the Ratio of Stimulant to Sedative Effects of Ketamine.
Topics: Adult; Alcoholism; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Genetic Predispos | 2016 |
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Topics: Adolescent; Adult; Aged; Alcoholism; Antidepressive Agents; Depressive Disorder, Major; Excitatory A | 2009 |
Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients.
Topics: Adult; Alcoholism; Brief Psychiatric Rating Scale; Chi-Square Distribution; Confidence Intervals; Ex | 2003 |
Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism.
Topics: Adult; Affect; Alcohol Drinking; Alcoholic Intoxication; Alcoholism; Brief Psychiatric Rating Scale; | 2004 |
Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism.
Topics: Adult; Affect; Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Synergism; Ethanol; Female; H | 2006 |
Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics.
Topics: Adolescent; Adult; Age of Onset; Alcoholic Intoxication; Alcoholism; Dose-Response Relationship, Dru | 1998 |
Dextromethorphan challenge in alcohol-dependent patients and controls.
Topics: Alcohol Drinking; Alcoholism; Behavior, Addictive; Dextromethorphan; Dextrorphan; Double-Blind Metho | 2000 |
Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists.
Topics: Adult; Affect; Alcoholism; Anxiety; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Ty | 2001 |
18 other studies available for ketamine and Alcohol Abuse
| Article | Year |
|---|---|
Intravenous ketamine for severe alcohol use disorder at Moi Teaching & Referral Hospital, Kenya: a case report.
Topics: Adult; Alcoholism; Hospitals; Humans; Kenya; Ketamine; Male; Naltrexone; Referral and Consultation; | 2023 |
One binge-type cycle of alcohol plus ketamine exposure induces emotional-like disorders associated with oxidative damage in adolescent female rats.
Topics: Alcoholism; Animals; Anxiety; Ethanol; Female; Ketamine; Oxidative Stress; Prefrontal Cortex; Rats | 2023 |
Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change.
Topics: Alcoholism; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Midazolam; Pilot Projects | 2020 |
Withdrawal from chronic ethanol exposure increases postsynaptic glutamate function of insular cortex projections to the rat basolateral amygdala.
Topics: Administration, Inhalation; Alcoholism; Animals; Basolateral Nuclear Complex; Central Nervous System | 2020 |
Effects of long-term alcohol exposure on the pharmacokinetic profiles of ketamine and norketamine in rats.
Topics: Alcoholism; Animals; Chromatography, Liquid; Humans; Ketamine; Rats; Tandem Mass Spectrometry | 2021 |
Rapid tolerance to behavioral effects of ethanol in rats: Prevention by R-(-)-ketamine.
Topics: Alcoholism; Animals; Behavior, Animal; Drug Tolerance; Ethanol; Hand Strength; Isomerism; Ketamine; | 2021 |
Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz.
Topics: Alcohol Drinking; Alcoholism; Antidepressive Agents; Humans; Ketamine; Naltrexone; Narcotic Antagoni | 2019 |
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect-Reply.
Topics: Alcoholism; Antidepressive Agents; Depression; Humans; Ketamine; Naltrexone; Receptors, Opioid | 2019 |
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect.
Topics: Alcoholism; Antidepressive Agents; Depression; Humans; Ketamine; Naltrexone; Receptors, Opioid | 2019 |
Alcohol Use Disorder as a Possible Predictor of Electroconvulsive Therapy Response.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcoholism; Anesthesia; Anesthetics, Dissociative; Benz | 2017 |
Multiple drug use and polydrug use amongst homeless traveling youth.
Topics: Adolescent; Alcoholism; Cross-Sectional Studies; Female; Homeless Youth; Humans; Illicit Drugs; Keta | 2008 |
Ketamine as a primary predictor of out-of-body experiences associated with multiple substance use.
Topics: Adolescent; Adult; Alcoholism; Amphetamine-Related Disorders; Delusions; Female; Humans; Ketamine; M | 2011 |
Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
Topics: Adult; Alcoholism; Antidepressive Agents; Bipolar Disorder; Cross-Over Studies; Double-Blind Method; | 2012 |
Sexual identity and drug use harm among high-risk, active substance users.
Topics: Adolescent; Adult; Aged; Alcoholism; Bisexuality; British Columbia; Crack Cocaine; Cross-Sectional S | 2013 |
Substance use and related problems: a study on the abuse of recreational and not recreational drugs in Northern Italy.
Topics: Accidents, Traffic; Adult; Alcoholism; Amphetamines; Anxiety; Crack Cocaine; Depression; Female; Hal | 2006 |
[Experience in using ketamine preparations in the psychotherapy of alcoholism].
Topics: Adult; Alcoholism; Combined Modality Therapy; Female; Humans; Infusions, Intravenous; Ketamine; Male | 1994 |
[The use of psychedelic agents in psychotherapy (apropos the article by Iu. P. Sivolap and V. A. Savchenkov "Experience in using ketamine preparations in the psychotherapy of alcoholism")].
Topics: Alcoholism; Combined Modality Therapy; Humans; Ketamine; Psychotherapy; Psychotropic Drugs | 1996 |
[Treatment of alcoholism by affective counterattribution].
Topics: Abreaction; Adult; Alcohol Drinking; Alcoholism; Humans; Ketamine; Male; Middle Aged; Narcotherapy | 1989 |